Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key

Executive Summary

Will activist investors succeed in unlocking Bristol-Myers Squibb's shareholder value - or instead orchestrate a takeover worth more than $100bn?


Related Content

Combinations Continue To Drive Immuno-Oncology Deal-Making
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
Bristol Teams Up With Billionaire-Backed Parker Institute On IO Research
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts